1-hexadecyl-2-acetyl-glycero-3-phosphocholine has been researched along with Cardiomegaly in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 2 (66.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| DeMello, D; Lagunoff, D; Ohar, JA; Waller, KS | 1 |
| Ono, S; Voelkel, NF | 1 |
| Atakhanov, ShE; Iurenev, AP; Mazaev, AV; Men'shikov, MIu; Tkhostov, EB | 1 |
3 other study(ies) available for 1-hexadecyl-2-acetyl-glycero-3-phosphocholine and Cardiomegaly
| Article | Year |
|---|---|
Administration of chronic intravenous platelet-activating factor induces pulmonary arterial atrophy and hypertension in rabbits.
Topics: Animals; Atrophy; Cardiomegaly; Hemodynamics; Hypertension, Pulmonary; Infusions, Intravenous; Lung; Platelet Activating Factor; Pulmonary Artery; Rabbits | 1991 |
PAF antagonists inhibit monocrotaline-induced lung injury and pulmonary hypertension.
Topics: Animals; Azepines; Cardiomegaly; Hypertension, Pulmonary; Lung; Lung Injury; Male; Monocrotaline; Platelet Activating Factor; Rats; Rats, Inbred Strains; Triazoles | 1991 |
[Calcium metabolism in arterial hypertension. I. Myocardial hypertrophy and hormone-dependent increase in Ca2+ levels in the thrombocytes of patients with arterial hypertension].
Topics: Adenosine Diphosphate; Adult; Aged; Blood Platelets; Calcium; Cardiomegaly; Humans; Hypercalcemia; Hypertension; In Vitro Techniques; Male; Middle Aged; Models, Cardiovascular; Platelet Activating Factor | 1988 |